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Introduction: Use of postoperative radiotherapy (PORT) in non–
small-cell lung cancer remains controversial. Limited data indicate 
that PORT may benefit patients with involved N2 nodes. This study 
evaluates this hypothesis in a large retrospective cohort treated with 
chemotherapy and contemporary radiation techniques.
Methods: The National Cancer Data Base was queried for patients 
diagnosed 2004–2006 with resected non–small-cell lung cancer and 
pathologically involved N2 (pN2) nodes also treated with chemo-
therapy. Multivariable Cox proportional hazards model was used to 
assess factors associated with overall survival (OS). Inverse prob-
ability of treatment weighting (IPTW) using the propensity score was 
used to reduce selection bias. OS was compared between patients 
treated with versus without PORT using the adjusted Kaplan–Meier 
estimator and weighted log-rank test based on IPTW.
Results: Two thousand and one hundred and fifteen patients were 
eligible for analysis. 918 (43.4%) received PORT, 1197 (56.6%) did 
not. PORT was associated with better OS (median survival time 42 
months with PORT versus 38 months without, p = 0.048). This effect 
was significant in multivariable and IPTW Cox models (hazard ratio: 
0.87, 95% confidence interval: 0.78–0.98, p = 0.026, and hazard 
ratio: 0.89, 95% confidence interval: 0.79–1.00, p = 0.046, respec-
tively). No interaction was seen between the effects of PORT and 
number of involved lymph nodes (p = 0.615).
Conclusions: PORT was associated with better survival for patients 
with pN2 nodes also treated with chemotherapy. No interaction 
was seen between benefit of PORT and number of involved nodes. 
These findings reinforce the benefit of PORT for N2 disease in mod-
ern practice using the largest, most recent cohort of chemotherapy-
treated pN2 patients to date.
Key Words: Non–small-cell lung cancer, Radiotherapy, PORT, 
Adjuvant therapy.
(J Thorac Oncol. 2015;10: 462–471)
The use of postoperative radiotherapy (PORT) for resected non–small-cell lung cancer (NSCLC) remains contro-
versial. A large meta-analysis of PORT trials demonstrated 
a survival detriment associated with PORT,1 although subset 
analysis indicated that this detriment may not apply to those 
with N2 disease. Despite criticism of the PORT meta-analysis 
regarding inclusion of older trials which used outdated radia-
tion equipment and techniques, as well as inclusion of unpub-
lished data, the use of PORT has declined significantly since 
the publication of the PORT meta-analysis.2 The detriment in 
overall survival (OS) seen with PORT was felt to largely be 
due to excessive late radiation toxicity to normal tissues, par-
ticularly the heart and lungs.3,4
More recent publications, however, have bolstered the 
use of PORT, especially in the setting of pN2 disease. A sub-
set analysis of the Adjuvant Navelbine International Trialist 
Association (ANITA) trial suggested a benefit in OS for 
patients with N2 disease treated with PORT, regardless of the 
use of adjuvant chemotherapy.5 In addition, an analysis using 
the Surveillance, Epidemiology, and End Results (SEER) 
database similarly indicated that PORT was associated with 
improved survival for patients with N2 disease.6 However, 
SEER analyses carry significant limitations, including lack of 
detail regarding radiotherapy (RT) treatment and the absence 
of chemotherapy information.
This study sought to determine if PORT for pN2 dis-
ease improves OS in patients treated with chemotherapy and 
contemporary radiation techniques. The National Cancer Data 
Base NSCLC database was utilized for this analysis, which 
contains detailed radiation therapy information as well as 
receipt of chemotherapy data. This analysis was limited to 
patients with pN2 disease who received chemotherapy, as the 
OS benefit conferred with the addition of chemotherapy for 
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pN2 patients has been well established after publication of 
multiple randomized trials,7–10 and is considered standard of 
care. In addition, all patients in this analysis were treated on 
linear accelerators in the 3D conformal RT era.
PATIENTS AND METHODS
The NCDB is a large, prospectively acquired data-
base gathered and maintained by the American College of 
Surgeons, the Commission on Cancer, and the American 
Cancer Society. The database draws on information gath-
ered from Commission on Cancer-accredited cancer centers 
nationwide and currently captures 70% of all newly diagno-
ses malignancies in the United States. The data set includes 
detailed information on patient characteristics, disease 
parameters, treatment information, and outcomes. The treat-
ment information contains data not available in other large 
national databases, including detailed RT information regard-
ing treatment site, treatment source, radiation dose (Gy), and 
treatment technique as well as receipt of chemotherapy infor-
mation. The database is subdivided into primary sites, and an 
institution may apply for access to the data regarding a par-
ticular site. Emory University has been granted access to the 
NCDB NSCLC database, which contains 1,547,531 patients 
diagnosed between 1998 and 2011.
The primary goal of this study was to determine if PORT 
for pathologic stage III NSCLC improves OS in a modern cohort 
of patients treated with chemotherapy and contemporary RT 
techniques. A secondary goal of the analysis was to determine if 
a benefit from PORT may depend on the number of involved N2 
nodes. To address these questions, the NCDB NSCLC lung can-
cer database was queried for patients diagnosed between 2004 
and 2006 with pathologic N2 (pN2) nodal disease treated with 
primary resection. Currently, survival outcomes are not yet avail-
able for patients diagnosed after 2006 within the NCDB, thus the 
inclusion years at diagnosis for this study end at 2006. Inclusion 
criteria were as follows: non–small-cell histology, pN2, no evi-
dence of metastatic disease, and receipt of chemotherapy, and 
one lifetime cancer or cases where the reported tumor was the 
first of multiple diagnoses. Exclusion criteria excluded patients 
diagnosed at the reporting facility but treated elsewhere; patients 
treated with cobalt-60 teletherapy, cesium-137, gamma knife, 
stereotactic radiosurgery, any type of radiation other than beam, 
patients with radiation doses less than 3500 cGy or greater than 
7000 cGy, patients treated with neoadjuvant RT, intraoperative 
RT, or patients with unknown RT schedules, patients with posi-
tive or unknown margin status, patients that received palliative 
care, and patients with unknown survival information. Patient 
and disease parameters were examined, including facility type, 
sex, age, race, insurance status and type, median income in area 
of residence, education, rurality or urban influence of county, 
Charlson–Deyo comorbidity score,11,12 year of diagnosis, his-
tology, tumor grade, pathologic T stage, treatment with che-
motherapy, number of regional lymph nodes (LN) examined, 
and number of regional LN involved. Although chemotherapy 
sequence (adjuvant versus neoadjuvant) is not coded in the 
NCDB, chemotherapy sequence was approximated by determin-
ing for each case the number of days between diagnosis and the 
definitive surgical procedure versus the number of days between 
diagnosis and the first administration of chemotherapy. Facility 
type was determined by the Commission on Cancer. Insurance 
was categorized as none, private, or government, which included 
Medicare, Medicaid, and other government insurance. Education 
was defined as the proportion of adults that did not graduate high 
school in the patient’s area of residence. OS was defined as the 
number of months between the most definitive surgical proce-
dure on the primary site and the last contact or date of death.
Statistical Analysis
Statistical analysis was conducted using SAS Version 
9.313. Descriptive statistics for each variable were reported. 
The univariate association of each covariate with receipt of 
postoperative RT was assessed using the χ2 test for categorical 
covariates and ANOVA for numerical covariates. The univari-
ate association of each covariate with OS was assessed using 
Cox proportional hazards models and log-rank tests. A multi-
variable Cox model was fit including postoperative RT and the 
covariates. A backward variable selection method was used to 
select the covariates applying an alpha = 0.20 removal criteria. 
In addition, a model was fit to test for an interaction between 
postoperative RT and number of positive LN.
To reduce the treatment selection bias, a propensity 
score weighting method was also implemented.14 Propensity 
scores were calculated to model the main effect of treatment. 
A logistic regression model was used to calculate propensity 
scores including the covariates that were marginally associated 
with survival in univariate or multivariable analysis (p < 0.20): 
sex, insurance, income, education, urban/rural, Charlson–
Deyo comorbidity score, histology, grade, pathologic T stage, 
regional LN positive, regional LN examined, and age. A sec-
ond set of propensity scores was created to model an interac-
tion between treatment and number of LN positive (less than 3 
versus greater than or equal to 3). The four possible combina-
tions of treatment and number of LN positive were used as the 
outcome in the propensity score model so that covariates would 
be balanced across all four groups. A nominal logistic regres-
sion model was used to calculate propensity scores instead of 
a binary logistic regression. The number of regional LN exam-
ined was not included in the second propensity score model 
because it was too strongly related to number of LN positive.
Inverse probability of treatment weights (IPTW) were 
calculated from the propensity scores and represented the 
inverse probability of a participant receiving the observed 
treatment based on their characteristics. IPTW estimates were 
further stabilized by multiplying them by the marginal prob-
ability of receiving the treatment observed. For all analysis, 
the weights were normalized to add up to the original sam-
ple size. The effectiveness of the weighting was evaluated 
by calculating the standardized differences of the covariates 
between patients treated with and without PORT, weighting 
by the IPTW in the total sample and within each positive LN 
group.15 The treatment effects were recalculated using the 
IPTW with a Cox model including receipt of PORT; and a 
Cox model including receipt of PORT, number of LN positive, 
and their interaction. Adjusted Kaplan–Meier survival curves 
using IPTW and the weighted log-rank test were generated 
comparing treatment groups.16
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RESULTS
In the NSCLC NCDB, 2115 patients diagnosed between 
2004 and 2006 were eligible for analysis. Complete patient 
characteristics are presented in Table 1. Of the eligible 
patients, 918 (43.4%) received PORT and 1197 (56.6%) did 
not. As for the chemotherapy sequencing, 1730 (81.79%) 
received adjuvant chemotherapy, 192 (9.1%) received neoad-
juvant chemotherapy, and the sequence was unknown for 193 
(9.1%). Patients were more likely to receive PORT if treated 
at a Comprehensive Community Cancer Center or other 
community center (versus academic center, p < 0.001), had 
private insurance (p < 0.001), lived in an area with median 
income between $30,000 and $45,999 (versus less than 
$30,000 or greater than $46,000, p = 0.038), had Charlson–
Deyo score of 0 (versus 1 or 2+, p = 0.001), had less than or 
equal to 3 regional LN examined (p < 0.001), or were younger 
in age (p < 0.001).
Median OS for patients treated with PORT was signifi-
cantly longer than for those not treated with PORT on propen-
sity-weighted log-rank analysis (42 months versus 38 months, 
TABLE 1.  Patient Descriptive Statistics According to Receipt of PORT
Characteristic Total (n = 2115)
PORT
p ValueaNo (N = 1197) Yes (N = 918)
Facility typeb
  Community Cancer Program/other 170 (8.0%) 81 (6.77%) 89 (9.69%) <0.001b
  Comprehensive Community Cancer Program 1098 (51.9%) 594 (49.62%) 504 (54.9%)
  Academic/Research Program (includes NCI) 847 (40%) 522 (43.61%) 325 (35.4%)
Sex
  Men 991 (46.9%) 550 (45.95%) 441 (48.04%) 0.340
  Woman 1124 (53.1%) 647 (54.05%) 477 (51.96%)
Age
  Median 64 65 62 <0.001b
  Range 27–89 27–89 30–84
Race
  White 1831 (87.5%) 1026 (86.95%) 805 (88.17%) 0.402
  Other 262 (12.5%) 154 (13.05%) 108 (11.83%)
Insurance
  Not insured 41 (2.0%) 23 (1.95%) 18 (1.99%) <0.001b
  Private insurance 963 (46.3%) 492 (41.77%) 471 (52.1%)
  Govt. insurance 1078 (51.8%) 663 (56.28%) 415 (45.91%)
Income
  <$30,000 252 (12.5%) 151 (13.36%) 101 (11.43%) 0.038b
  $30,000–$34,999 387 (19.2%) 195 (17.26%) 192 (21.72%)
  $35,000–$45,999 539 (26.8%) 297 (26.28%) 242 (27.38%)
  $46,000 + 836 (41.5%) 487 (43.1%) 349 (39.48%)
Urban/rural
  Metro area 1655 (82.9%) 937 (83.66%) 718 (81.87%) 0.292
  Urban/rural 342 (17.1%) 183 (16.34%) 159 (18.13%)
Charlson–Deyo score
  0 1292 (61.1%) 692 (57.81%) 600 (65.36%) 0.001b
  1 638 (30.2%) 396 (33.08%) 242 (26.36%)
  2+ 185 (8.7%) 109 (9.11%) 76 (8.28%)
Year of diagnosis
  2004 673 (31.8%) 357 (29.82%) 316 (34.42%) 0.079
  2005 694 (32.8%) 405 (33.83%) 289 (31.48%)
  2006 748 (35.4%) 435 (36.34%) 313 (34.1%)
Histology
  Large cell carcinomas 131 (6.2%) 76 (6.35%) 55 (5.99%) 0.761
  Squamous cell carcinomas 502 (23.7%) 288 (24.06%) 214 (23.31%)
  Adenocarcinomas 1407 (66.5%) 787 (65.75%) 620 (67.54%)
  Adenosquamous carcinomas 75 (3.5%) 46 (3.84%) 29 (3.16%)
(Continued)
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p = 0.048, Fig. 1). The 5-year OS rate was 39.8% for those who 
received PORT versus 34.7% for those who did not receive 
PORT. The complete results of the univariate and multivariable 
analysis of OS are found in Tables 2 and 3, respectively. On 
univariate analysis of survival, use of PORT was associated 
with a strong trend toward better survival (hazard ratio [HR]: 
0.91, 95% confidence interval [CI]: 0.82–1.01, p = 0.071). On 
multivariable analysis, PORT was significantly associated with 
better OS (HR: 0.87, 95% CI: 0.77–0.98, p = 0.021). Other fac-
tors associated with better survival on multivariable analysis 
were younger age (p < 0.001), women sex (p < 0.001), living in 
a higher income area (p = 0.028), living in an urban/rural versus 
metro county (p = 0.034), adenocarcinoma histology compared 
with adenosquamous carcinoma (p = 0.003), lower T stage 
(p < 0.001), 1–2 involved LN versus greater than or equal to 3 
(p < 0.001), and higher number of examined LN (p < 0.001). A 
summary of the IPTW analyses of OS is found in Table 4. On 
IPTW Cox analysis, PORT was significantly associated with 
better OS (HR: 0.89, 95% CI: 0.79–1.00, p = 0.046). No inter-
action was seen between the effect of PORT and the number of 
positive LN (p = 0.615).
DISCUSSION
The role of PORT in resected stage III lung cancer 
has remained controversial since publication of the PORT 
meta-analysis in 1998. Although an OS detriment was 
observed in patients receiving PORT, this study has been 
criticized due to the use of antiquated RT equipment and 
techniques. Such outdated factors include use of cobalt-60 
equipment, which leads to inhomogeneous dose distribution, 
along with unsophisticated 2D field design. Taken together, 
these factors likely increased the volume of normal tissue 
exposed to high dose radiation. Such technical factors likely 
substantially worsened the treatment mortality associated 
with PORT by simultaneously limiting the effectiveness of 
the therapy and increasing the likelihood of severe radia-
tion pneumonitis.3 The obsolete nature of the PORT meta-
analysis data limits its applicability to modern practice, yet 
limited data have emerged to determine the potential role for 
PORT in the setting of involved N2 nodes.5,6,17–28 Data jus-
tifying the use of PORT in addition to adjuvant chemother-
apy are even more limited, with the largest study being the 
ANITA secondary analysis (224 pN2 patients, 118 received 
chemotherapy).5
This study suggests that in this retrospective cohort, 
PORT was associated with an OS benefit in patients with pN2 
disease who received chemotherapy. The addition of PORT 
was associated with significantly prolonged median survival, 
from 38 to 42 months. This effect did not seem to be depen-
dent on the number of involved LN. Although a larger series 
Grade
  1 107 (5.1%) 66 (5.51%) 41 (4.47%) 0.085
  2 877 (41.5%) 520 (43.44%) 357 (38.89%)
  3 936 (44.3%) 509 (42.52%) 427 (46.51%)
  4 81 (3.8%) 46 (3.84%) 35 (3.81%)
  Unknown 114 (5.4%) 56 (4.68%) 58 (6.32%)
AJCC Pathologic T stage
  T0/1 712 (33.8%) 386 (32.36%) 326 (35.67%) 0.092
  T2 1147 (54.4%) 671 (56.24%) 476 (52.08%)
  T3 114 (5.4%) 69 (5.78%) 45 (4.92%)
  T4 134 (6.4%) 67 (5.62%) 67 (7.33%)
Regional nodes positive
  1–2 987 (49.5%) 568 (50.49%) 419 (48.22%) 0.314
  ≥3 1007 (50.5%) 557 (49.51%) 450 (51.78%)
  Median 3 2 3
  Range 1–34 1–34 1–20
Regional nodes examined
  1–3 221 (11.7%) 93 (8.74%) 128 (15.53%) <0.001b
  4–6 344 (18.2%) 194 (18.23%) 150 (18.2%)
  7–9 351 (18.6%) 217 (20.39%) 134 (16.26%)
  >9 972 (51.5%) 560 (52.63%) 412 (50%)
  Median 10 10 9.5
  Range 1–68 1–68 1–55
aANOVA for numerical covariates and χ2 test for categorical covariates.
bSignificant.
PORT, postoperative radiotherapy; NCI, National Cancer Institute; AJCC, American Joint Committee on Cancer.
TABLE 1. (Continued)
Characteristic Total (n = 2115)
PORT
p ValueaNo (N = 1197) Yes (N = 918)
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using SEER data indicated that the benefit of PORT may be 
limited to those with over 50% of resected LN involved with 
disease, the lack of chemotherapy data in that study limits its 
relevance to modern practice.26
The use of the NCDB affords significant advantages over 
previous studies designed to address the efficacy of PORT for 
pN2 NSCLC. With a large patient population and comprehen-
sive data including detailed RT information such as radiation 
dose, treatment site, treatment source and treatment technique 
coupled with receipt of chemotherapy data, the NCDB allows 
for an analysis of PORT in patients treated with more modern, 
up-to-date therapies. By limiting the analysis to those treated 
with contemporary RT and chemotherapy, this retrospective 
cohort provides data which suggest that PORT may be benefi-
cial for pN2 patients treated in current practice.
Continuous advancements in RT technology over the 
past few decades and the resultant improvements in the thera-
peutic ratio of radiation likely contribute to the emerging ben-
efit of PORT in the era of adjuvant chemotherapy. The advent 
of three-dimensional (3D) treatment planning, 3D conformal 
RT, and intensity-modulated radiotherapy have allowed for 
delivery of more conformal RT for lung cancer with less tox-
icity to surrounding normal lung and thoracic structures.29–36 
Implementation into RT practice of on-board imaging, which 
involves the acquisition of images by the treatment machine 
to improve setup accuracy, and respiratory motion control dur-
ing RT delivery have allowed for reduced setup error, which 
has in turn reduced field margins and the volume of normal 
tissue irradiated.37–43 In the setting of unresectable disease, 
rates of pneumonitis have continued to decline in the past few 
decades. The rate of grade 3 pneumonitis in the Radiation 
Therapy Oncology Group (RTOG) trial 9410, which com-
pleted enrollment in 1998, was 11%.44 A recent study, RTOG 
0617, which completed enrollment in 2011, revealed a grade 
3 pneumonitis rate of 5%.45 A previous report showed that 
when meta-analysis of PORT data was limited to trials which 
used linear accelerators, PORT was associated with better 
local control and OS.17 It should be noted, however, that the 
trials analyzed by Billiet et al. were underpowered, limiting 
the conclusions able to be drawn.46 The association between 
PORT and better OS seen in this study is not surprising, as 
the analysis was limited to the recent complete data available 
in the NCDB and patients treated with cobalt were excluded.
The OS benefit imparted by chemotherapy for resected 
NSCLC results from reduction in both local and distant fail-
ure.8,47 Per the ANITA study, adjuvant chemotherapy reduced 
distant failure from 28 to 25% and local failure from 18 to 
12%. In this study, at least 82% of patients received adjuvant 
chemotherapy and 9% received neoadjuvant chemotherapy, 
although the chemotherapy sequence would not be expected 
to affect survival advantage afforded by chemotherapy.10 The 
use of PORT allows for further reductions in the rate of local 
failure, improving survival beyond that afforded by chemo-
therapy alone. A meta-analysis of concurrent versus sequen-
tial chemoradiotherapy in the definitive treatment setting for 
stage III NSCLC demonstrated that improved local control 
leads to better OS.48 Thus, improvements in local control in the 
resected stage III patient population using PORT would also 
be likely to improve survival. Although the current analysis 
lacks local control data (local control is not recorded within 
the NCDB), it would be expected that the OS benefit seen in 
this study may be related to reductions in local failure.
The value of PORT for N2 disease is currently being 
evaluated in a prospective randomized trial in Europe. The 
Intergroupe Francophone de Cancerologie Thoracique initiated 
the Lung Adjuvant Radiotherapy Trial (LungART), a phase III 
randomized trial assessing the benefit of conformal PORT after 
surgery for patients with completely resected pN2 disease.49 
Patients may receive either neoadjuvant or adjuvant chemo-
therapy and must be treated using small volume 3D conformal 
FIGURE 1.  Adjusted Kaplan–Meier 
survival estimates and weighted log-
rank test.
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TABLE 2.  Univariate Analysis of Overall Survival
Covariate Level N
OS (Months)
Hazard Ratio (95% CI) HR p Value Log-Rank p Value
Postoperative radiation Yes 918 0.91 (0.82–1.01) 0.073 0.071
No 1197 - -
RT regional dose >60 Gy 67 1.04 (0.78–1.39) 0.793 0.226
50–60 Gy 436 0.88 (0.77–1.01) 0.066
<50 Gy 415 0.92 (0.80–1.05) 0.207
No postop radiation 1197 - -
Facility type Academic/Research Program (includes NCI) 847 0.84 (0.69–1.02) 0.083 0.219
Comprehensive Community Cancer Program 1098 0.86 (0.71–1.04) 0.122
Community Cancer Program/other 170 - -
Sex Men 991 1.29 (1.16–1.43) <0.001 <0.001a
Woman 1124 - -
Patient age 2115 1.01 (1.01–1.02) <0.001 -
Race Other 262 0.93 (0.79–1.09) 0.376 0.375
White 1831 - -
Insurance Not insured 41 1.14 (0.81–1.62) 0.450 <0.001a
Private insurance 963 0.79 (0.71–0.88) <0.001
Govt. insurance 1078 - -
Income <$30,000 252 1.25 (1.06–1.48) 0.010 0.017a
$30,000–$34,999 387 1.19 (1.02–1.37) 0.023
$35,000–$45,999 539 1.16 (1.01–1.32) 0.031
$46,000 + 836 - -
Urban/rural Urban/rural 342 1.01 (0.88–1.17) 0.875 0.876
Metro area 1655 - -
Charlson–Deyo score 2+ 185 1.22 (1.02–1.47) 0.034 0.014a
1 638 1.15 (1.03–1.29) 0.016
0 1292 - -
Year of diagnosis 2004 673 0.94 (0.83–1.07) 0.356 0.332
2005 694 1.04 (0.91–1.18) 0.584
2006 748 - -
Histology Squamous cell carcinomas 502 1.11 (0.98–1.25) 0.111 0.002a
Large cell carcinomas 131 1.22 (0.98–1.51) 0.074
Adenosquamous carcinomas 75 1.56 (1.20–2.04) <0.001
Adenocarcinomas 1407 - -
Grade Unknown 114 1.07 (0.77–1.50) 0.689 0.038a
4 81 1.64 (1.16–2.33) 0.005
3 936 1.20 (0.93–1.55) 0.155
2 877 1.14 (0.88–1.48) 0.309
1 107 - -
AJCC Pathologic T 4 134 1.64 (1.32–2.03) <0.001 <0.001a
3 114 1.49 (1.17–1.88) <0.001
2 1147 1.25 (1.11–1.40) <0.001
0/1 712 - -
Regional nodes positive ≥3 1007 1.30 (1.17–1.45) <0.001 <0.001a
1–2 987 - -
Regional nodes examined >9 972 0.79 (0.67–0.94) 0.009 0.073
7–9 351 0.82 (0.67–1.01) 0.056
4–6 344 0.82 (0.67–1.00) 0.047
1–3 221 - -
aSignificant.
OS, overall survival; HR, hazard ratio; RT, radiotherapy; CI, confidence interval; NCI, National Cancer Institute; AJCC, American Joint Committee on Cancer.
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RT. The target volumes specified on this trial involve only 
the bronchial stump, the ipsilateral hilum, and the involved 
mediastinal LN stations, plus a small margin. The treated area 
within the chest is therefore significantly reduced relative to the 
volumes treated during the earlier days of PORT (Fig. 2). The 
trial further specifies a prescription dose of 54 Gy. Both the 
target volumes and the prescription dose used in LungART are 
consistent with the current standards of practice. The results of 
LungART will be informative and will definitively answer the 
question of the value of PORT for pN2 NSCLC.
This analysis does carry some limitations beyond its ret-
rospective design. Although the NCDB does have advantages 
TABLE 3.  Multivariable Analysis of Overall Survival
Covariate Level
OS (Months)
Hazard Ratio HR p Value Type 3 p Value
Postoperative radiation Yes 0.87 (0.77–0.98) 0.021 0.021a
No - -
Sex Men 1.23 (1.09–1.38) <0.001 <0.001a
Woman - -
Patient age 1.01 (1.01–1.02) <0.001 <0.001a
Insurance Not insured 1.29 (0.87–1.90) 0.201 0.087
Private insurance 0.90 (0.78–1.03) 0.133
Govt. insurance - -
Income <$30,000 1.26 (1.03–1.53) 0.022 0.028a
$30,000–$34,999 1.25 (1.06–1.48) 0.009
$35,000–$45,999 1.14 (0.99–1.32) 0.075
$46,000 + - -
Urban/rural Urban/rural 0.83 (0.70–0.99) 0.034 0.034a
Metro area - -
Histology Squamous cell carcinomas 1.00 (0.87–1.16) 0.966 0.013a
Large cell carcinomas 1.21 (0.95–1.54) 0.130
Adenosquamous carcinomas 1.55 (1.16–2.07) 0.003
Adenocarcinomas - -
AJCC Pathologic T stage 4 1.58 (1.25–2.01) <0.001 <0.001a
3 1.33 (1.01–1.76) 0.042
2 1.25 (1.10–1.42) <0.001
0/1 - -
Regional nodes positive ≥3 1.48 (1.30–1.68) <0.001 <0.001a
1–2 - -
Regional nodes examined >9 0.59 (0.48–0.72) <0.001 <0.001a
7–9 0.67 (0.54–0.84) <0.001
4–6 0.68 (0.54–0.84) <0.001
1–3 - -
Number of observations in the original data set = 2115. Number of observations used = 1730. Backward selection with an alpha level of removal of 0.20 was used. The following 
variables were removed from the model: Charlson/Deyo score, facility type, grade, year of diagnosis, and race.
aSignificant.
OS, overall survival; HR, hazard ratio; AJCC, American Joint Committee on Cancer.
TABLE 4.  Analysis of Overall Survival Using Inverse Probability of Treatment Weighting with the Propensity Score
Covariate
OS (Months)
Hazard Ratio HR p Value Type3 p Value
Main effects modela
  Postoperative radiation: Yes vs. No 0.89 (0.79–1.00) 0.046 0.046
Interaction modelb
  Interaction: postoperative radiation with regional lymph nodes positive - - 0.615
aModel included postoperative radiation. Number of observations used was 1730.
bModel included postoperative radiation, regional lymph nodes positive, and their interaction. Number of observations used was 1831.
OS, overall survival; HR, hazard ratio.
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over other large datasets, including large sample size, con-
sistency of data drawn from across the United States, inclu-
sion of chemotherapy data, and detailed RT information, the 
NCDB is limited by the potential for miscoding and incre-
mental survival data. Also, although the most modern avail-
able cohort from the NCDB was used, some of the patients 
included in the analysis were treated up to 10 years ago. In 
addition, follow-up time is somewhat short particularly given 
that late radiation toxicities can influence survival. The analy-
sis also lacks toxicity, treatment compliance, and quality of 
life data, which is important information for this group of 
patients that can be relatively tenous after undergoing surgi-
cal resection and adjuvant chemotherapy. Such factors may 
have influenced long-term survival results. In addition, stag-
ing techniques used within this group are not available, which 
could have also affected survival outcomes. However, contem-
porary staging procedures such as positron emission tomogra-
phy–computed tomography and magnetic resonance imaging 
of the brain were considered standard of care at the time of the 
study period, so lack of staging information would likely not 
change the conclusions of this study significantly.
This study did analyze radiation dose (less than 50 Gy, 
50–60 Gy, and greater than 60 Gy) as a variable for OS in 
univariate analysis (Table 1), and it did not seem to be signifi-
cant. However, more specific radiation details such as dose to 
normal tissues including lung V20, mean lung dose, and mean 
heart dose were not available within this data set. Dosimetric 
data would be valuable; however, this very specific radiation 
data will likely only be available in the context of randomized 
trials and is beyond the capabilities of the NCDB.
Caution should be taken when interpreting studies, such 
as the present one, which are based on retrospective patient 
cohorts. In this study, for example, the better survival seen in 
patients treated with PORT suggests a benefit in patients with 
resected NSCLC. However, patients treated with PORT in this 
cohort tended to be younger and have lower co-morbidity, which 
also suggests that selection bias may have affected the results.
Despite these limitations, this analysis provides data 
supporting the benefit of PORT in OS for patients with pN2 
disease. This conclusion is in line with current practice guide-
lines, which indicate that PORT is an acceptable therapy to be 
given in addition to chemotherapy for patients with resected 
pN2 disease. The survival benefit of PORT appears to be addi-
tive in this retrospective population when given along with 
chemotherapy and shows no dependence upon number of 
involved LN. Though caution should be taken when interpret-
ing studies based on retrospective cohorts, evidence of the 
value of PORT in the adjuvant treatment paradigm in patients 
with pN2 NSCLC continues to build. The results of the pend-
ing LungART randomized trial should provide a more defini-
tive answer to this persistent clinical question.
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FIGURE 2.  Representative “Beam’s Eye View” from a single anterior–posterior field from a modern course of postoperative radio-
therapy (A) and out-of-date postoperative radiotherapy (B) for a patient with a completely resected right upper lobe tumor found 
to have involved N2 nodes. The borders for the field on the right (B) were derived from the specifications of the Medical Research 
Council (MRC) Lung Cancer Working Party randomized trial of postoperative radiotherapy, a trial included in the PORT meta-analy-
sis. The MRC study mandated coverage of the entire mediastinum, bilateral hila, bronchial stump, and, in the case of an upper lobe 
tumor, the bilateral supraclavicular fossae. These field specifications resulted in significantly higher volumes of normal heart and lung 
in the treatment field than what is currently acceptable. In addition, with older radiotherapy equipment (such as Cobalt-60 units), 
less penetrating, lower energy beams were used, which resulted in higher superficial dose relative to the dose at the desired target 
depth. This created significant dose inhomogeneity with the highest dose level deposited in uninvolved lung, chest wall, and heart. 
Contoured normal structures seen in this figure are the lungs (purple), the heart (pink), and the esophagus (orange).
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not responsible for the analytic or statistical methodology 
employed, or the conclusions drawn from these data by the 
investigator.
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